Business ❯ Biotechnology

Pharmaceuticals

Drug Development Acquisitions Clinical Trials Cancer Treatment Vaccine Development Biosimilars Oncology Research and Development Manufacturing Gene Therapy Clinical Development Immuno-oncology Cancer Therapies Regulatory Affairs Contract Manufacturing Mergers and Acquisitions Drug Discovery Contract Development and Manufacturing Biologics Manufacturing Company Activities mRNA Therapies Clinical Research Patents Biontech MEI Pharma Arrowhead Pharmaceuticals Neuromodulators Pet Pharmaceuticals Biopharmaceuticals Investment in AI Genetic Research Corporate Governance Stock Market Biotech Stocks Vaccines Drug Delivery Systems Alzheimer's Disease RNA Drugs Collaborations Roivant Sciences Weight Loss Psychedelics Obesity Treatments Partnerships Autoimmune Diseases Cancer Research Corporate Finance Obesity Treatment Radiopharmaceuticals Plasma Fractionation Cancer Treatments Vertex Pharmaceuticals

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Open‑label Phase 1b/2a findings are guiding a randomized Phase 2b now enrolling that is slated to deliver top‑line data in Q3 2026.

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

Samsung Biologics to Buy GSK’s Human Genome Sciences Campus for $280 Million

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Law Firms Press MoonLake Class Action Over SLK Claims as Lead‑Plaintiff Deadline Nears

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

Hyperliquid Strategies Closes Sonnet Deal, PURR to Debut on Nasdaq

Arrowhead Gains FDA Approval for Redemplo as Results Surge and Shares Hit Three-Year High

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma

Cidara Gains on JP Morgan Coverage Initiation as ESWI Presentation Nears

AstraZeneca Licenses Algen’s AI-Guided CRISPR Discoveries in Deal Worth Up to $555 Million

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory